A 24-week Study Evaluating the Effectiveness and Safety of Lucentis® 0.2mg in Retinopathy of Prematurity Participants in China - Trial NCT05576792
Access comprehensive clinical trial information for NCT05576792 through Pure Global AI's free database. This phase not specified trial is sponsored by Novartis Pharmaceuticals and is currently Recruiting. The study focuses on Retinopathy of Prematurity. Target enrollment is 55 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Novartis Pharmaceuticals
Novartis
Timeline & Enrollment
N/A
Jan 13, 2023
May 16, 2024
Primary Outcome
Number of participants with absence of active Retinopathy of Prematurity (ROP) and absence of unfavorable structural outcomes in both eyes during the observational period after starting study treatment.
Summary
This is a 24-week, multicenter, open-label, single-arm, observational, post approval
 commitment study, which is designed to collect effectiveness, safety and other clinical
 information of intravitreal ranibizumab 0.2 mg for the treatment of Retinopathy of
 Prematurity (ROP) participants in a real world clinical setting in mainland China.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05576792
Non-Device Trial